title: Combined therapy in treatment of murine infection by Fusarium solani.
abstract: OBJECTIVE
  We evaluated the efficacy of voriconazole, amphotericin B and micafungin alone and combined in a murine model of disseminated infection by Fusarium solani.
  
  
  METHODS
  Immunosuppressed mice were treated with voriconazole at 60 mg/kg/day, amphotericin B at 3 mg/kg/day, micafungin at 10 mg/kg/day or combinations of these antifungal drugs. For survival studies, treatment began 1 day after infection and continued for 10 days. For tissue burden studies, animals were sacrificed on day 6 of the treatment and the fungal load in the kidneys and spleens was measured. The experiments were carried out using two different clinical strains of F. solani.
  
  
  RESULTS
  Only the combination of voriconazole plus amphotericin B prolonged the survival of the mice versus the controls for the two strains tested. However, this combination only reduced tissue burden in the kidney and spleen of mice infected by one strain. The other treatments were clearly less effective.
  
  
  CONCLUSIONS
  Voriconazole plus amphotericin B may have a role in the treatment of fusariosis.
authors.affiliation: Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Reus, Spain.
authors.forename: Mery
authors.initials: M
authors.lastname: Ruíz-Cendoya
authors.forename: Marçal
authors.initials: M
authors.lastname: Mariné
authors.forename: Josep
authors.initials: J
authors.lastname: Guarro
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015169:Colony Count, Microbial; D004359:Drug Therapy, Combination; D054714:Echinocandins / Q000008:administration & dosage / Q000627:therapeutic use; D005670:Fusarium / Q000187:drug effects*; D016867:Immunocompromised Host; D007668:Kidney / Q000382:microbiology; D055666:Lipopeptides; D008074:Lipoproteins / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D000077551:Micafungin; D051379:Mice; D009181:Mycoses / Q000188:drug therapy* / Q000382:microbiology*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D013154:Spleen / Q000382:microbiology; D016019:Survival Analysis; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D011743:Pyrimidines; D014230:Triazoles; D000666:Amphotericin B; D065819:Voriconazole; D000077551:Micafungin